eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Flynn Pharma Ltd

Alton House, 4 Herbert Street, Dublin 2, Republic of Ireland,
Telephone: +44 (0)1438 727822
Fax: +44 (0)1438 727805
WWW: http://www.flynnpharma.com
Medical Information Direct Line: +44 (0)1438 727822
Medical Information e-mail: medinfo@flynnpharma.com
Customer Care direct line: +44 (0)1773 510 123
Medical Information Fax: +44 (0)1438 727805

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 21/12/2011
SPC Medikinet XL 5mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   12-Jul-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

In Section 4.2 The following section has changed to read:

Medikinet XL should not be taken too late in the morning as it may cause disturbances in sleep. However, if the effect of the medicinal product wears off too early in the evening, disturbed behaviour may recur.

A small dose of an immediate-release methylphenidate hydrochloride tablet late in the day may help to solve this problem. In that case, it could be considered that adequate symptom control might be achieved with a twice daily immediate-release methylphenidate regimen. The pros and cons of a small evening dose of immediate-release methylphenidate versus disturbances in falling asleep should be considered.

Treatment should not continue with Medikinet XL if an additional late dose of immediate-release methylphenidate is required, unless it is known that the same extra dose was also required for a conventional immediate-release regimen at equivalent breakfast/lunchtime dose.


In Section 4.4 the following wording has been added to the end of the "aggressive or hostile behaviour" section:

...., bearing in mind that upwards or downwards titration may be appropriate .  Treatment interruption can be considered.

In Section 10 the revised date is 12th July 2011
Updated on 24/08/2011 and displayed until 21/12/2011
Reasons for adding or updating:
  • New SPC for new product
Date of revision of text on the SPC:  
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

None provided

Active Ingredients/Generics

 
   methylphenidate hydrochloride